SEC Form 4 · accession 0001562180-18-003561
BIO-TECHNE Corp · TECH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kim Kelderman
Officer — President, Diagnostics & Genom
Period of report
Aug 8, 2018
Accepted (ET)
Aug 10, 2018 · 4:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000842023
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Aug 8, 2018 | A | 1,691 | A | — | — | Common Stock | 1,691 | 1,691 | D |
| Stock Options (Right to buy)F3 | $177.32 | Aug 8, 2018 | A | 12,044 | A | — | Aug 8, 2025 | Common Stock | 12,044 | 12,044 | D |
| Stock Options (Right to buy)F2 | $177.32 | Aug 8, 2018 | A | 9,033 | A | — | Aug 8, 2025 | Common Stock | 9,033 | 9,033 | D |
| Restricted Stock UnitsF1,F4 | — | holding | — | — | — | — | May 1, 2025 | Common Stock | 5,000 | 5,000 | D |
| Stock Options (Right to buy)F5 | $150.78 | holding | — | — | — | — | May 1, 2025 | Common Stock | 2,652 | 2,652 | D |
| Stock Options (Right to buy)F6 | $150.78 | holding | — | — | — | — | May 1, 2025 | Common Stock | 7,348 | 7,348 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F2Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F3Vests 3,011 shares each on 8/8/2019, 8/8/2020, 8/8/2021, 8/8/2022
- F4Vests 1667 shares on 5/1/2019, 1,666 shares each on 5/1/2020 and 1,667 shares on 5/1/2021
- F5663 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022
- F61,837 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022